Optipro TIN Suspension

Adult dose

Typically, 1 pouch is orally administered three times daily after meals for adults.

This medication should not be administered to patients with congenital branched-chain amino acid metabolism disorders. Such patients are at risk of severe symptoms like seizures or respiratory distress. When using this medication, gastrointestinal symptoms such as constipation, diarrhea, abdominal distension, discomfort, and vomiting may occasionally occur, so caution is necessary. If these symptoms occur, the dosage should be reduced or administration should be temporarily halted. It may affect kidney function, potentially resulting in increased BUN levels in the blood; therefore, dosage adjustment may be necessary if kidney dysfunction is suspected. Due to metabolic disorders, blood ammonia levels may rise; immediate dosage adjustments are required if such symptoms appear. It may also affect liver function, potentially causing increases in AST, ALT, and bilirubin levels, as well as symptoms such as skin rash, itching, facial or leg swelling, erythema, and facial flushing. This medication should only be used in patients with low serum albumin levels and cirrhosis who meet specific conditions. In cases of diabetes or hepatic encephalopathy, careful assessment of dietary intake and appropriate dietary guidance must be provided. This medication should not be used in patients with severe hepatic encephalopathy or high total bilirubin levels, nor in those with greatly impaired liver function as it will be ineffective. This medication only contains branched-chain amino acids and does not provide all necessary amino acids, thus sufficient protein and caloric intake according to the patient's condition is essential. Patients requiring protein restriction should be cautious as there is a risk of worsening nutritional status. Long-term use may lead to elevated BUN and ammonia levels in the blood, so overdose should be avoided and regular monitoring of condition is necessary. If hypoalbuminemia does not improve after 2 months of use, alternative treatment methods should be considered. Elderly patients may have reduced physical capability leading to higher risks of metabolic disorders; therefore, administration should be conducted with caution. The safety of this medication has not been established in pregnant or nursing women, so it should only be used when the benefits outweigh the risks. The safety in children has not been confirmed; hence there is no clinical experience with its use in this population. This medication should be stored out of reach of children, and caution should be taken to avoid transferring it to other containers, as this may lead to accidents or degradation of quality.

Mild side effects

• Constipation
• diarrhea
• abdominal distension
• abdominal discomfort
• nausea
• abdominal pain
• vomiting
• loss of appetite
• epigastric pain
• thirst

This medication should be stored in a container that can block light and air, at room temperature between 1 to 30 degrees Celsius. Storing it this way will help maintain the drug's effectiveness and prevent deterioration.

Appearance

A viscous suspension that is white to pale yellow with a fragrance, contained in an aluminum foil pouch.

Package unit

30 pouches (1 pouch (20g) x 30)